Pharming Group (PHAR) Stock Forecast & Price Target

PHAR price $12.20 -0.06 -0.49%

Ticker
PHAR
Price
$12.20
Change
-0.06 -0.49%
Market cap ?
$855.16M
P/E ?
72.04
Forward P/E ?
52.04
Dividend yield ?
0.00%
Beta ?
0.09
Sector
Healthcare
Industry
Biotechnology
Stocklytics score
47
Value
49
Quality
58
Growth
34

Stocklytics score rationale: value 49, quality 58, growth 34.

Financials

2016201720182019202020212022202320242025
16693660107517335154575611189389000212174000198871000205622000245316000297200000376134000

Pharming Group N.V. is a biopharmaceutical company dedicated to the creation and commercialization of protein replacement therapies and precision medicines. The firm concentrates its efforts on addressing rare diseases and critical unmet medical needs across the United States, Europe, and other international markets. Its primary commercialized product is Ruconest, a recombinant human C1 esterase inhibitor utilized…

Forecast

Consensus Buy from 3 analysts. Average price target $39.00, +219.7% versus the current price. Low $38.00. High $40.00.

Insights · Dividends · Forecast · Financials · Learn

Stocklytics home · Screener

Analysts have an average 12-month price target of $39.00 for Pharming Group (PHAR), 223.4% above the current price of $12.06. Of 3 analysts covering the stock, 3 rate it Buy or Strong Buy, 0 Hold, and 0 Sell or Strong Sell, giving a consensus of Buy.

Forecasts are third-party estimates and often wrong. They are not investment advice.

PHAR price target

12-month price target
Low$38.00
Average$39.00
High$40.00

The average is 223.4% above the current price of $12.06.

Is Pharming Group a buy or sell?

Of 3 analysts, 3 rate Pharming Group Buy or Strong Buy, 0 Hold, and 0 Sell or Strong Sell. The consensus label is Buy. That split is not a recommendation.

Pharming Group earnings and revenue forecast

Analyst averages on file: 2026, EPS $0.23, revenue $378.78 million. 2027, EPS $0.21, revenue $392.76 million.

PHAR score and fair value

The Stocklytics Score for PHAR is 47 out of 100. It averages value, quality, and growth against a large-cap US universe. It is not a price target and not a buy or sell rating. Fair value is a separate estimate on the fair value tab.

PHAR forecast FAQs

What is the PHAR price target?

$39.00 average, with a published range of $38.00 to $40.00.

Is Pharming Group a buy or sell?

The consensus is Buy from 3 analysts. This is not a recommendation.

What is the Pharming Group stock forecast for 2026?

Analysts' average EPS estimate for 2026 on file is $0.23. The average revenue estimate is $378.78 million.

What will PHAR be worth in 2030?

No reliable forecast exists that far out.

When is Pharming Group's next earnings report?

The next earnings date is shown on the stock page when a future report is on the calendar. This forecast does not invent a date.

Related: Pharming Group · Financials · Dividends · Compare · AI stocks

Capital is at risk. Stocklytics is operated by Stocklytics Inc., a Marshall Islands company. It is not regulated by the FCA and does not give investment advice.

Pharming Group (PHAR) Stock Forecast & Price Target

PHAR$12.20-0.06 -0.49%

$855.16M

Market Cap

72.04

P/E

52.04

Forward P/E

47

Score

Price History